Published in Biochemistry on July 21, 2017
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem (2011) 2.74
SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res (2011) 2.46
Inhibition of the shade avoidance response by formation of non-DNA binding bHLH heterodimers. EMBO J (2009) 2.20
The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem (2007) 1.89
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One (2012) 1.77
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta (2007) 1.50
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol (2008) 1.50
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab (2003) 1.41
Structure-function analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol (2010) 1.40
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Structural prediction of peptides bound to MHC class I. J Mol Biol (2005) 1.33
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol (2013) 1.31
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res (2013) 1.25
Fast docking using the CHARMM force field with EADock DSS. J Comput Chem (2011) 1.25
Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. Proteins (2007) 1.25
Model structure of human APOBEC3G. PLoS One (2007) 1.24
Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2010) 1.22
CD3 delta establishes a functional link between the T cell receptor and CD8. J Biol Chem (2002) 1.20
CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers. J Biol Chem (2005) 1.18
A combined computational and functional approach identifies new residues involved in pH-dependent gating of ASIC1a. J Biol Chem (2010) 1.17
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 1.16
The V-ATPase proteolipid cylinder promotes the lipid-mixing stage of SNARE-dependent fusion of yeast vacuoles. EMBO J (2011) 1.12
Functional dynamics of PDZ binding domains: a normal-mode analysis. Biophys J (2005) 1.11
Shaping the interaction landscape of bioactive molecules. Bioinformatics (2013) 1.09
How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding. Proteins (2006) 1.08
Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J Virol (2006) 1.08
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Res (2014) 1.08
Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol (2003) 1.07
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol (2012) 1.06
Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues. J Am Chem Soc (2005) 1.04
Structural and functional interaction sites between Na,K-ATPase and FXYD proteins. J Biol Chem (2004) 1.03
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
EADock: docking of small molecules into protein active sites with a multiobjective evolutionary optimization. Proteins (2007) 1.00
Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex. Biophys J (2008) 1.00
Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics (2012) 1.00
SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 1.00
SwissSidechain: a molecular and structural database of non-natural sidechains. Nucleic Acids Res (2012) 0.99
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer (2011) 0.99
The fourth transmembrane segment of the Na,K-ATPase alpha subunit: a systematic mutagenesis study. J Biol Chem (2004) 0.99
SwissBioisostere: a database of molecular replacements for ligand design. Nucleic Acids Res (2012) 0.98
Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med (2009) 0.98
Sequence determinants of a microtubule tip localization signal (MtLS). J Biol Chem (2012) 0.95
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A (2008) 0.94
How T cell receptors interact with peptide-MHCs: a multiple steered molecular dynamics study. Proteins (2011) 0.94
Two-step mechanism of induction of the gene expression of a prototypic cancer-protective enzyme by diphenols. Chem Res Toxicol (2008) 0.93
Blind docking of 260 protein-ligand complexes with EADock 2.0. J Comput Chem (2009) 0.93
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol (2007) 0.92
Molecular basis of leukocyte rolling on PSGL-1. Predominant role of core-2 O-glycans and of tyrosine sulfate residue 51. J Biol Chem (2002) 0.91
Expanding molecular modeling and design tools to non-natural sidechains. J Comput Chem (2012) 0.89
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. Oncol Rep (2012) 0.89
RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family. RNA Biol (2013) 0.89
Frequent MAGE mutations in human melanoma. PLoS One (2010) 0.87
Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior. J Biol Chem (2007) 0.87
Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses. J Virol (2011) 0.87
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires. PLoS One (2011) 0.85
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. J Med Chem (2012) 0.85
In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos (2008) 0.85
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer (2013) 0.84
Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction. J Biol Chem (2010) 0.84
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Cancer Immunol Immunother (2007) 0.83
Use of the FACTS solvation model for protein-ligand docking calculations. Application to EADock. J Mol Recognit (2010) 0.83
Structural assessment of single amino acid mutations: application to TP53 function. Hum Mutat (2006) 0.83
The peroxisomal enzyme L-PBE is required to prevent the dietary toxicity of medium-chain fatty acids. Cell Rep (2013) 0.81
Improving binding affinity and stability of peptide ligands by substituting glycines with D-amino acids. Chembiochem (2013) 0.81